Clinical trial
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating…
NCT00085124 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085124 |
|---|---|
| Title | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia |
| Official title | A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 Years |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8, 21)(q22 and 2 more |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, cytarabine, daunorubicin hydrochloride, laboratory biomarker analysis |
| Enrollment | 500 |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2007 |
| First posted | Jun 11, 2004 |
| Last update posted | May 30, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: